Put differently, the conjunction of DHT and BRAF/MEK inhibitors can effectively block the pathways of STAT3/SOX2 and MAPK, decrease the growth and spread of drug-resistant primary melanoma cells, and promote apoptosis. Here, SOX2 is linked to melanoma.